Nuveen
VRTX icon

Nuveen’s Vertex Pharmaceuticals VRTX Stock Holding History

Nuveen’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-20,000
Closed -$1.49M – 1623
2013
Q4 		$1.49M Buy
+20,000
New +$1.39M 0.01% 900

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nuveen's VRTX Position: Q2 2026 in Review

Nuveen reduced its Vertex Pharmaceuticals (VRTX) stake by 0.26% in Q2 2026, selling an estimated $1.25M and leaving 1,081,685 shares worth $537M. The position accounts for 0.13% of the portfolio, ranked #125.

Nuveen first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.01B in Q2 2020. 1,763 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Nuveen held 1,081,685 shares of Vertex Pharmaceuticals worth $537M as of Q2 2026.
  • Nuveen sold 2,810 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.25M.
  • Vertex Pharmaceuticals made up 0.13% of Nuveen's portfolio in Q2 2026, its #125 holding.
  • Nuveen first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Nuveen's Vertex Pharmaceuticals position peaked at $1.01B in Q2 2020.
  • 1,763 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.